Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

OBJECTIVES: Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients. METHODS: Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled trial (NCT02969525). After Week 48, patients could e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Asahina, Akihiko, Gladman, Dafna D, Tanaka, Yoshiya, Tillett, William, Ink, Barbara, Assudani, Deepak, de la Loge, Christine, Coarse, Jason, Eells, Jason, Gossec, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891423/
https://www.ncbi.nlm.nih.gov/pubmed/35789257
http://dx.doi.org/10.1093/rheumatology/keac353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891423/
https://www.ncbi.nlm.nih.gov/pubmed/35789257
http://dx.doi.org/10.1093/rheumatology/keac353

Ejemplares similares